157. Back to Basics - Early Bladder Cancer

This week, we explore muscle-invasive bladder cancer (MIBC). This space has made significant progress with the completion of two pivotal trials. The first was VESPER, comparing two chemotherapy regimens. The key to this trial may be the amount of cisplatin delivered, but there are some unknowns in a real-world setting. It also compared the neoadjuvant to the perioperative space. The second trial utilises immunotherapy in the perioperative landscape and is the first trial to so but only used one chemotherapy regimen.

A must-listen to episode comparing the complexities of early bladder cancer and the options available.

Studies discussed in the episode:

VESPER

NIAGARA

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [e-mail]

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.

---

Hosted on Acast. See acast.com/privacy for more information.